latanoprost (xalatan) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Latanoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is also known by the brand name of Xalatan manufactured by Pfizer. Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss. Latanoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to the biologically active acid. The active acid of latanoprost reaching the systemic circulation is primarily metabolized by the liver to the 1,2-dinor and 1,2,3,4-tetranor metabolites via fatty acid β-oxidation.   NCATS

Chemistry

  • SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC2=CC=CC=C2
  • InChIKey: GGXICVAJURFBLW-CEYXHVGTSA-N
  • Mol. Mass: 432.5928
  • ALogP: 4.19
  • ChEMBL Molecules:
    latanoprost  
    latanoprostene bunod  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: Yes

Drug Pricing (per unit)

United States

$0.3533 - $85.7746

Australia

$4.5200
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( latanoprost (xalatan), netarsudil )

Alternative names

(15r)-latanoprost | bol 303259-x | bol-303259-x | bol303259-x | isopropyl (z)-7-((1r,2r,3r,5s)-3,5-dihydroxy-2-((3r)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate | latanoprost | latanoprostene bunod | latanoprostum | liposomal latanoprost | monopost | monoprost | ncx116 | ncx 116 | ncx-116 | pf-03187207 | pf3187207 | pf 3187207 | pf-3187207 | pfizer brand of latanoprost | phxa34 | phxa41 | phxa 41 | phxa-41 | propan-2-yl (5z)-7-{(1r,2r,3r,5s)-3,5-dihydroxy-2-[(3r)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate | t2345 | t-2345 | xa-41 | xalatan

Organizations (141)

Research & Development (127)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (20)

Approved Indications (3)


 

Glaucoma

Glaucoma, Open-Angle

Ocular Hypertension

Experimental Indications - Clinical Trial Phases 1-4 (20)


 

Alopecia Areata (Phase 4)

Blood Pressure (Phase 4)

Corneal Diseases (Phase 3)

Diabetic Retinopathy (Phase 4)

Dry Eye Syndromes (Phase 4)

Eye Diseases (Phase 4)

Glaucoma ()

Glaucoma, Angle-Closure (Phase 4)

Glaucoma, Open-Angle ()

Graves Ophthalmopathy (Phase 4)

Healthy Volunteers (Phase 4)

Intraocular Pressure (Phase 2)

Macular Edema (Phase 4)

Meniere Disease (Phase 2)

Ocular Hypertension ()

Pharmacological and Toxicological Phenomena (Phase 2)

Pigmentation (Phase 4)

Tears (Phase 4)

Uveitis, Anterior (Phase 4)

Vitiligo (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 213
  • # of Trial Organizations: 127

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue